|Shares Out. (in M):||12||P/E||18.6||0|
|Market Cap (in $M):||66||P/FCF||18.6||0|
|Net Debt (in $M):||-5||EBIT||6||0|
Brainjuicer Group, a highly differentiated market research business, is a long-term compounder offered at a better than fair price. The company is run by a highly engaged and inspirational entrepreneur, John Kearon, who is on a mission to change the market research business and build a large business in the process. While the shares have recently performed well, the probability of the business being materially larger in 3, 5 and 7 years is high. The company has a fine balance sheet, requires little-to-no capital, produces great cash flows and is prudently managed from a capital perspective. Attractive ongoing growth in the core business ought to result in at least a low-teens IRR, while recent new business launches, yet to prove themselves, could propel the company much beyond the base case.
Brainjuicer is a market research company. The company is highly differentiated in that it pioneered the use of behavioral economics and System-1/System-2 thinking in market research. The company's founder is a believer in the System-1 brain as it relates to product decision making by consumers. The emotional brain dominates the decision making process is his view - which runs counter to most of the research business today. After of a number of years, Kahneman's book, Thinking Fast and Slow, helped to popularize the emotional brain and provided a boost to the business. Today, the company offers a variety of research products, including ad testing and brand tracking, developed on this differentiated view. It operates around the globe and for the biggest brands. It is considered to be a highly differentiate firm, having appeared at the top of GRIT report each of the last four years as the most innovative market research agency in world... and by a large margin against all the industry heavyweights (http://www.greenbookblog.org/2016/05/13/the-top-20-most-innovative-market-research-suppliers-a-grit-2016-sneak-peek/).
The Chief Brainjuicer, as he is recognized, is a highly infectious evangalist for the System-1 approach to marketing and market research. He continues to own 28% of the company and is clearly the voice and inspirational leader of the company. John founded the business in 1999 after working advertising agency Publicis and as a brand manager for Unilver. Today he is widely recognized (though not always agreed with) in the research business and is synonymous with advent of behavioral economics in market research. He is focused on building Brainjuicer into a very large company and taking market share. Here are a few videos:
Growth Over the Years:
While the growth in the business has been impressive over the years - 1 mm to over 25 mm in 12 years, there has been a clear slowdown in the growth in recent years. This was attributable mostly to an underlying shift if the product mix over the more recent years. The company splits its business into 2 pieces: (1) Juicy - the clearly differentiated System-1 products; and (2) Twist - more traditional products with a little company "twist". That later category has been deemphasized over the years as the core products continued to gain acceptance. In fact, twist revenues peaked in 2011 at over 9 mm and nearly 44% of revenue before falling to 4 mm in 2015 or 16% of revenue. Juicy (the differentiated core and future of the business), now is 84% of revenue and has compounded at nearly 20% over the last five years. Below is the mix through 2015:
Below is the company's new updated reporting of revenue by product. As the company transitioned away from Twist to predominantly Juicy, there were some other changes going on within Juicy. Most notably, Juice Generation, a consulting oriented business which was not scalable, did not translate into core business growth and wass senior management heavy to deliver was ultimately deemphasized. The company now really has focused on quantitative Juicy products. As you can see, this core product set has continued to grow at high teens the last few years - in GP terms. In H2 this year GP from this product set grew 26.4% and was 85% of total GP.
The business is quite a global business and the company's success in the US over the last several years is particularly noteworthy... having compounded at over 18% over the last five years. This US exposure has been a help as of late with the exchange rate changes. Below is the business performance over the last several years by geography:
H1 2016 results confirmed that the core business was quite healthy and growing. Revenue growth of 12% was accompanied by GP growth of 15%. GP growth has been growing more than revenue given product mix changes. Normalized pre-tax profit was up 22%. As mentioned, GP growth from the core product set was quite impressive at 26.4% (though some help from GBP/USD exchange). Also, the company released a trading statement late last week highlighting anticipated results above expectations, with particularly strong language around the company's core products.
The company rates highly on capital allocation. The company pays a dividend and occasional large special dividends, including a 12p payment after the recent interim results. Historically the company has also repurchased shares at attractive prices. Just this year, the company has purchased nearly 900,000 shares at 395p. It was aggressively trying to repurchase additional blocks, though as a smaller company with limited liquidity was only able to accomplish that which it did. The company has also passed on aggressively priced acquisitions over the years.
New Business / New Products:
Valuation and Return Potential:
Substantially all of earnings converts into FCF. I expect the company to finish 2016 with 6 mm net cash. With a 66 mm market cap and 60 mm EV, the company is trading at 18.6x net earnings ('16) and 16.9x net of cash. For reference, just over 18x appears to be the median for a sample of market research and advertising businesses around the globe. Brainjuicer would appear to have much better organic growth before it and a much better balance sheet. My conservative estimates going forward suggest 9% revenue growth and 12% NPAT growth over the next 4 years. With even a 15x multiple net of cash, Brainjuicer would seem to be in a position to deliver a low teens IRR under conservative assumptions. This gives little credit to the two new business launches mentioned.
|Entry||01/27/2017 02:06 PM|
In a short period, the shares have continued to perform beyond most expectations, but importantly, the company's January trading update showed material strength and an acceration in the business. Growth in GP acclerated to 18.4% in H2 from 11% in H1 on a constant currency basis. On a reported basis, GP was up 27% for the year. Two of the company's biggest product lines and biggest sources of growth (ad testing and brand tracking) grew 97% in H2 which was up from 59% in H1 and now represent nearly 40% of GP (these figures are not adjusted for currency, which did have a material impact). Cash generation has remained strong, as the company ended the year with 7.8 mm of net cash.
While no longer as cheap as at the time of write-up, I continue to believe the company will compound at a rate that produces a meaningful return from these prices. For those looking for such ideas, the company remains an interesting study.